Roles of FoxM1 in cell regulation and breast cancer targeting therapy

2017 ◽  
Vol 34 (3) ◽  
Author(s):  
Xin Song ◽  
Samuel Selorm Fiati Kenston ◽  
Jinshun Zhao ◽  
Danting Yang ◽  
Yuanliang Gu
Keyword(s):  
Breast Cancer ◽  
Cancer Targeting ◽  
Cell Regulation ◽  
Targeting Therapy

scholarly journals Development of a Fundamental Technology to Seek Drug Targets, and Its Application to Cancer Targeting Therapy

2018 ◽  
Vol 138 (7) ◽  
pp. 903-909
Author(s):  
Kazuya Nagano ◽  
Kazuma Higashisaka ◽  
Shin-ichi Tsunoda ◽  
Yasuo Tsutsumi
Keyword(s):  
Drug Targets ◽  
Cancer Targeting ◽  
Targeting Therapy

scholarly journals Telomerase as a Possible Candidate Targeting Therapy in Different Breast Cancer Cell Lines

2020 ◽  
Vol 21 (8) ◽  
pp. 2243-2250
Author(s):  
Salma Aboelela ◽  
Abeer Ashmawy ◽  
Sabry Shaarawy ◽  
Mohammed EL- Hefny ◽  
Amina Medhat
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Targeting Therapy

Sensitive and Specific Detection of Breast Cancer Lymph Node Metastasis Through Dual-Modality Magnetic Particle Imaging and Fluorescence Molecular Imaging: a Preclinical Evaluation

2021 ◽  
Author(s):  
Guorong Wang ◽  
Guangyuan Shi ◽  
Yu Tian ◽  
Lingyan Kong ◽  
Ning Ding ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Magnetic Particle ◽  
Cancer Targeting ◽  
Node Metastasis ◽  
Magnetic Particle Imaging ◽  
Particle Imaging ◽  
Fluorescence Molecular Imaging ◽  
Biosafety Evaluation

Abstract Purpose: A sensitive and specific imaging method to detect metastatic cancer cells in lymph nodes (LNs) to detect the early-stage breast cancer is urgently needed. The purpose of this study was to investigate a novel breast cancer-targeting and tumour microenvironment ATP-responsive superparamagnetic iron oxide (SPIOs) imaging probe that was developed to detect lymph node metastasis (LNMs) through fluorescence molecular imaging (FMI) and magnetic particle imaging (MPI). The imaging nanoprobe comprised of SPIOs conjugated with breast cancer-targeting peptides (CREKA) and an ATP-responsive DNA aptamer (dsDNA-Cy5.5), abbreviated as SPIOs@A-T. Methods: SPIOs@A-T was synthesised and characterized for its imaging properties, targeting ability and toxicity in vitro. Mice with metastatic lymph node (MLN) of breast cancer were established to evaluate the FMI and MPI imaging strategy in vivo. Healthy mice with normal lymph node (NLN) were used as control group. Histological examination and biosafety evaluation were performed for further assessment. Results: After injection with SPIO@A-T, the obvious high fluorescent intensity and MPI signal were observed in MLN group than those in NLN group. MPI could also complement the limitation of imaging depth from FMI, thus could detect MLN more sensitively. The combination of the imaging strengths of FMI and MPI ensured the detection of breast cancer metastases with high sensitivity and specificity, thereby facilitating the precision differentiation of malignant from benign LNs. Besides, the biosafety evaluation results showed SPIO@A-T had good biocompatibility. Conclusion: Due to the superior properties of tumour-targeting, detection specificity, and biosafety, the SPIOs@A-T imaging probe in combination with FMI and MPI can provide a promising novel method for the early and precise detection of LNMs in clinical practice.

Towards breast cancer targeting: Synthesis of tetrahydroindolocarbazoles, antibreast cancer evaluation, uPA inhibition, molecular genetic and molecular modelling studies

2019 ◽  
Vol 93 ◽  
pp. 103332
Author(s):  
Entesar M. Ahmed ◽  
Alaadin E. Sarhan ◽  
Dina H. El-Naggar ◽  
Reham R. Khattab ◽  
Mohamed El-Naggar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Modelling ◽  
Molecular Genetic ◽  
Cancer Targeting ◽  
Molecular Modelling Studies ◽  
Modelling Studies

scholarly journals The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs

Cells ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 763 ◽  
Author(s):  
Justin M Brown ◽  
Marie-Claire D Wasson ◽  
Paola Marcato
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Cancer Progression ◽  
Triple Negative ◽  
Gene Expression Regulation ◽  
Receptor Expression ◽  
Breast Cancers ◽  
Targeting Therapy ◽  
Non Coding Rnas

Treatment decisions for breast cancer are based on staging and hormone receptor expression and include chemotherapies and endocrine therapy. While effective in many cases, some breast cancers are resistant to therapy, metastasize and recur, leading to eventual death. Higher percentages of tumor-initiating cancer stem cells (CSCs) may contribute to the increased aggressiveness, chemoresistance, and worse outcomes among breast cancer. This may be particularly true in triple-negative breast cancers (TNBCs) which have higher percentages of CSCs and are associated with worse outcomes. In recent years, increasing numbers of long non-coding RNAs (lncRNAs) have been identified as playing an important role in breast cancer progression and some of these have been specifically associated within the CSC populations of breast cancers. LncRNAs are non-protein-coding transcripts greater than 200 nucleotides which can have critical functions in gene expression regulation. The preclinical evidence regarding lncRNA antagonists for the treatment of cancer is promising and therefore, presents a potential novel approach for treating breast cancer and targeting therapy-resistant CSCs within these tumors. Herein, we summarize the lncRNAs that have been identified as functionally relevant in breast CSCs. Furthermore, our review of the literature and analysis of patient datasets has revealed that many of these breast CSC-associated lncRNAs are also enriched in TNBC. Together, this suggests that these lncRNAs may be playing a particularly important role in TNBC. Thus, certain breast cancer-promoting/CSC-associated lncRNAs could be targeted in the treatment of TNBCs and the CSCs within these tumors should be susceptible to anti-lncRNA therapy.

scholarly journals Ly6C hi Monocytes Delivering pH‐Sensitive Micelle Loading Paclitaxel Improve Targeting Therapy of Metastatic Breast Cancer

2019 ◽  
Vol 29 (33) ◽  
pp. 1904596 ◽  
Author(s):  
Tianqun Lang ◽  
Xinyue Dong ◽  
Yan Huang ◽  
Wei Ran ◽  
Qi Yin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Ph Sensitive ◽  
Targeting Therapy

scholarly journals Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10

2018 ◽  
Vol 78 (6) ◽  
pp. 1404-1417 ◽  
Author(s):  
Adrien Nougarede ◽  
Nikolay Popgeorgiev ◽  
Loay Kassem ◽  
Soleilmane Omarjee ◽  
Stephane Borel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endoplasmic Reticulum ◽  
Cancer Targeting

Abstract 1625: Discovery of a breast cancer targeting peptide with anti-tumor activity

2010 ◽  
Author(s):  
Bettina Proneth ◽  
Wouter H. Driessen ◽  
Amin Hajitou ◽  
Fernanda I. Staquicini ◽  
Wadih Arap ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Targeting ◽  
Targeting Peptide ◽  
Anti Tumor Activity
Sign in / Sign up

Export Citation Format

Share Document